Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?

The Archetypal Orphan Drug Biotech Company Remains Loss-Making

Executive Summary

Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.

You may also be interested in...



Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties

Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.

Silence Signs Takeda Deal And Sets Sights On US

The resignation of David Horn Solomon last month was a setback for Silence but the company believes it will benefit from the growing prominence given to RNAi technology.

The Challenges Facing Paul Hudson At the Helm of Sanofi

Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel